Compare British American Tobacco PLC (BTI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs State Street SPDR S&P Biotech ETF — how do they compare? British American Tobacco PLC trades at $55.9 (market cap $122.36B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: British American Tobacco PLC pays a 5.88% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, British American Tobacco PLC nearer its low. Which is the better fit depends on your goals.
| BTI | XBI | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $66.70 | $164.28 |
52-Week Low | $50.39 | $86.92 |
Enterprise Value | $166.31B | — |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.9, down 2.02% today, with a bearish technical signal overall despite bullish oscillators. The company reported Q2 2026 EPS of $2.25, beating expectations, and maintains strong profitability with a 24.99% net income margin. Recent news highlights its strategic tech partnership with ITC Infotech and workforce restructuring to cut costs.
Outlook is mixed: strong fundamentals and a 66.67% analyst buy rating support upside, but technical weakness and regulatory risks pose challenges. The stock offers value with a P/E of 14.48 and dividend yield, yet faces headwinds from declining combustibles and debt levels.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
